Project Grant R01CA298839
Award Date
12/5/24
Completion Date
11/30/29
Dollars Obligated
$634K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Tulane University is focused on investigating the role of the long non-coding RNA CRNDE in hepatocellular carcinoma (HCC) and its impact on tumor-infiltrating lymphocytes (TILs). The total award amount is $468,139, with a project period from March 15, 2025 to February 28, 2030. The key objectives of this research project are to elucidate the molecular mechanisms by which HCC-derived CRNDE...
This Project Grant award, with Federal Grant ID K08CA290152, was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) to The Regents of the University of California, San Francisco. The $282,053 award, effective March 1, 2025 through February 28, 2030, supports research to investigate mechanisms of resistance to immunotherapy in hepatocellular carcinoma (liver cancer). The funded project aims to use single-cell techniques and spatial analysis to examine the role of...
This Project Grant award, titled "EXPLOITING THERAPEUTIC VULNERABILITIES IN HEPATOCELLULAR CARCINOMA (ELEVATE)", is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research). The $2,678,459 award aims to advance the understanding of molecular mechanisms regulating non-alcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) and develop novel combinatorial treatment approaches. The award supports four research projects, an administrative core, a...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) for $687,679 aims to functionally characterize the transcriptional regulatory landscape of hepatocellular carcinoma (HCC) in order to uncover novel tumor cell-intrinsic vulnerabilities. The research plan involves computationally establishing human HCC transcriptional master regulators (TMRs), validating their tumor cell-intrinsic functions using CRISPR interference and activation...
This $127,952 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support research at George Washington University to study the role of the enzyme HDAC11 in liver cancer progression. The research has two main aims: 1) to determine if HDAC11-mediated modifications to the splicing factor SF3B2 impact alternative mRNA splicing in liver cancer cells, and 2) to evaluate the potential of HDAC11-specific inhibitors as a new liver cancer treatment...
This $1,224,644 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to dissect a novel tumor-promoting axis involving the immune checkpoint protein B7-H4 in intrahepatic cholangiocarcinoma (CCA), a highly desmoplastic and deadly form of bile duct cancer. The 5-year award, effective August 2024, will leverage the awardee's (Icahn School of Medicine at Mount Sinai) expertise and preliminary data to: 1) elucidate the molecular...
This Project Grant award, with a total funding of $138,742, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The primary awardee, The Johns Hopkins University, will utilize single-cell RNA sequencing data to develop statistical methods for identifying cellular interactions that are altered by combination immunotherapy treatments in pancreatic ductal adenocarcinoma (PDAC). Additionally, the award will support experiments...
This Project Grant award, identified as K08CA286847, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The $171,135 award, effective March 10, 2025 through February 28, 2030, supports the "SMALL LIVER CANCER: DEVELOPMENT OF A MULTI-LEVEL INTERVENTION TO IMPROVE ACCESS TO CURE (LIVER:CURE)" project at Weill Medical College of Cornell University. The project aims to develop the principal investigator's capacity...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $536,836.00 to The University of Texas M.D. Anderson Cancer Center to conduct research on the delivery optimization of a transarterial ablative therapy for treating hepatocellular carcinoma (HCC). The research aims to develop mathematical models that accurately describe the thermal, hypoxic, and pH response of this therapeutic approach in biological tissues, and to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $176,712 to the University of Pittsburgh to conduct research on the role of CD91-mediated signaling in cancer immunosurveillance. The research aims to develop a new mouse model to test the importance of CD91 signaling in response to tumor-derived heat shock proteins (HSPs) for priming T cell responses against nascent, emerging tumors. The goal is to better understand the mechanisms by...